Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

EB2023 primes mitochondria for BCL2 dependence and induces pyroptotic cell death via AMPK signaling and the unfolded protein response

Matthew Villaume, Michael Davidson, Anna Skwarska, Maria Arrate, Liana Valin, Sovira Chaudhry, Benjamin Reisman, Ming Jiang, Andrew Monteith, Haley Ramsey, Sarah Olmstead, Agnieszka Gorska, Brent Ferrell, Brian Bachmann, Marina Konopleva, Michael Savona

Blood (2025) 146 (Supplement 1): 637.

https://doi.org/10.1182/blood-2025-637

Published: 2025

Journal Articles

VISTA contributes to disease progression in high-risk myelodysplastic syndrome

Raymond Zhang, Hyundong Yoon, Qianni Hu, Carly Fielder, Haley Ramsey, Agnieszka Gorska, C Henrique Serezani, Michael Savona, Brent Ferrell, Jeffrey Rathmell, Tae Kon Kim

Blood (2025) 146 (Supplement 1): 673.

https://doi.org/10.1182/blood-2025-673

Published: 2025

Journal Articles

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

Zhuoer Xie, Qianxing Mo, Sarah Buckley, David Sallman, Jeffrey Lancet, Michael Savona, Rami Komrokji, Mrinal Patnaik, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2025-3873

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Parth Patel, Michael Canonico, Hayley Hawkins, Michael Zargari, Kathryn Kennedy, Katherine Walsh, Erica Mittlebeeler, Bradley Yelvington, Laura Lee, Emily F. Mason, Kateryna Fedorov, Ashwin Kishtagari, Sanjay Mohan, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 7389.

https://doi.org/10.1182/blood-2025-7389

Published: 2025

Journal Articles

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

Michael Canonico, Parth Patel, Hayley Hawkins, Kateryna Fedorov, Katherine Walsh, Kathryn Kennedy, Erica Mittlebeeler, Sarah Profitt, Sanjay Mohan, Emily F. Mason, Ashwin Kishtagari, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 7388.

https://doi.org/10.1182/blood-2025-7388

Published: 2025

Journal Articles

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Guillermo Garcia-Manero, Uma Borate, Andrew Brunner, Bonnie Kiner-Strachan, Bart Scott, Yazan Madanat, Michael Savona, Elizabeth Griffiths, Aram Oganesian, Yuri Sano, Lixia Zhu, Gareth Tomlinson, Danna Chan, Harold Keer, James McCloskey

Blood (2025) 146 (Supplement 1): 491.

https://doi.org/10.1182/blood-2025-491

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

Impact of clonal hematopoiesis and BRAF mutation status on clinical outcomes in melanoma patients treated with immune checkpoint inhibitors

Mason Alford-Holloway, Joseph Van Amburg, Yash Pershad, Leo Luo, Michael Savona, Douglas Johnson, Alexander Bick, Ashwin Kishtagari

Blood (2025) 146 (Supplement 1): 7661.

https://doi.org/10.1182/blood-2025-7661

Published: 2025

Journal Articles

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Blood (2025) 146 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2025-2074

Published: 2025

Journal Articles

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Grace Mercadante, Joseph Van Amburg, Yash Pershad, Naimisha Marneni, Jamye O'Neal, Emily F. Mason, Shakthi Bhaskar, Eden Biltibo, Vivek Patel, Reena Jayani-Kosarzycki, Bhagirathbhai Dholaria, Adetola Kassim, Michael Savona, Olalekan Oluwole, Andrew Jallouk, Alexander Bick, Ashwin Kishtagari

Blood (2025) 146 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2025-4158

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Impact of RAS mutations on outcomes in newly diagnosed AML patients

Melanie Naranjo, Jamila Mammadova, Sarah Profitt, Bradley Yelvington, Callee Brooks, Kathryn Kennedy, Erica Mittlebeeler, Ashwin Kishtagari, Somedeb Ball, Sanjay Mohan, Michael Savona, Kateryna Fedorov

Blood (2025) 146 (Supplement 1): 7026.

https://doi.org/10.1182/blood-2025-7026

Published: 2025

Journal Articles

F1 subunit-specific ATP synthase inhibition disrupts AML mitochondrial metabolism distinctly from other electron transport chain inhibitors

Matthew Villaume, Valeria Impedovo, Michael Davidson, Yujin Lee, Maria Arrate, Agnieszka Gorska, Haley Ramsey, Marina Konopleva, Brian Bachmann, Stefano Tiziani, Michael Savona

Blood (2025) 146 (Supplement 1): 6103.

https://doi.org/10.1182/blood-2025-6103

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

Jamila Mammadova, Melanie Naranjo, Sarah Profitt, Bradley Yelvington, Callee Brooks, Kian Rahbari, Kathryn Kennedy, Erica Mittlebeeler, Somedeb Ball, Michael Savona, Ashwin Kishtagari, Sanjay Mohan, Kateryna Fedorov

Blood (2025) 146 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2025-1621

Published: 2025

Journal Articles

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Kateryna Fedorov, Kathryn Kennedy, Erica Mittlebeeler, Sarah Profitt, Bradley Yelvington, Callee Brooks, Ashwin Kishtagari, Sanjay Mohan, Michael Savona, Somedeb Ball

Blood (2025) 146 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2025-1666

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

EB2023 primes mitochondria for BCL2 dependence and induces pyroptotic cell death via AMPK signaling and the unfolded protein response

VISTA contributes to disease progression in high-risk myelodysplastic syndrome

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Addition of venetoclax to hypomethylating agent offers limited incremental benefit for patients with treatment-naïve TP53-mutated myelodysplastic syndromes

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Impact of clonal hematopoiesis and BRAF mutation status on clinical outcomes in melanoma patients treated with immune checkpoint inhibitors

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Impact of RAS mutations on outcomes in newly diagnosed AML patients

F1 subunit-specific ATP synthase inhibition disrupts AML mitochondrial metabolism distinctly from other electron transport chain inhibitors

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax

High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only